gip glp 1 dual agonist GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Tirzepatide, a dual GIP/GLP-1 receptor

10.1530/joe-22-0224 67 Romero-GmezM.LawitzE.ShankarR

SKK is the holder of the Evelyn Wyrzykowski Research Chair in Cardiology, Section of Cardiology, Department of Internal Medicine, University of Manitoba

In the large SUSTAIN and PIONEER trials, only about 2060% of the CRP reduction was explained by weight and glycaemia

tctmd.com Reduced burden of continuous therapy

Outstanding Questions GLP-1RA is a new type of drug for the treatment of T2MD

The benefits to health have led to the approval of semaglutide for treating kidney and heart fibrosis in the US, but the treatment potential is much wider, opening possibilities for treating cancer, psoriasis, polycystic ovary syndrome, sinus disease, obstructive sleep apnoea, Alzheimers, Parkinsons, liver disease, atherosclerosis (vascular disease) [6], asthma, some forms of nerve damage [2] and more